Damase, T.; Sukhovershin, R.; Zhang, M.; Kiss, D.; Cooke, J. Hospital-based RNA Therapeutics. Preprints2022, 2022010073. https://doi.org/10.20944/preprints202201.0073.v1
APA Style
Damase, T., Sukhovershin, R., Zhang, M., Kiss, D., & Cooke, J. (2022). Hospital-based RNA Therapeutics. Preprints. https://doi.org/10.20944/preprints202201.0073.v1
Chicago/Turabian Style
Damase, T., Daniel Kiss and John Cooke. 2022 "Hospital-based RNA Therapeutics" Preprints. https://doi.org/10.20944/preprints202201.0073.v1
Abstract
Hospital-based programs democratize mRNA therapeutics by facilitating the processes to translate a novel RNA idea from the bench to the clinic. Because mRNA is essentially biological software, therapeutic RNA constructs can be rapidly developed. The generation of small batches of clinical grade mRNA to support IND applications and first-in-man clinical trials, as well as personalized mRNA therapeutics delivered at the point-of-care, is feasible at a modest scale of cGMP manufacturing. Advances in mRNA manufacturing science and innovations in mRNA biology, are increasing the scope of mRNA clinical applications.
Biology and Life Sciences, Biochemistry and Molecular Biology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.